Prasol Chemicals Share Price

Intimation about updation in CIN of the Company

• BSE India
• 3 days 14 hours ago

Submission of Transcript of Quarterly earnings call for Q1 FY 27 results

• BSE India
• 3 days 16 hours ago

<h3><span style="font-size:16px;"><strong>Specialty Chemicals company Prasol Chemicals announced Q1FY27 results</strong></span></h3> <p _ngcontent-ng-c1037862221=""><strong _ngcontent-ng-c1037862221="">Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c1037862221=""><strong _ngcontent-ng-c1037862221="">Revenue from Operations:</strong> Stood at Rs 4,336.46 million in Q1FY27, reflecting a YoY growth of 35.70% compared to Rs 3,195.60 million in Q1FY26. Sequentially, the revenue increased by 29.48% QoQ from Rs 3,349.12 million in Q4FY26. For the full year FY26, the revenue from operations was Rs 12,325.93 million.</li> <li _ngcontent-ng-c1037862221=""><strong _ngcontent-ng-c1037862221="">Total Income:</strong> Reached Rs 4,353.57 million in Q1FY27, marking an increase of 35.86% YoY from Rs 3,204.36 million in Q1FY26 and a growth of 29.12% QoQ from Rs 3,371.83 million in Q4FY26. The total income for the entire FY26 stood at Rs 12,378.45 million.</li> <li _ngcontent-ng-c1037862221=""><strong _ngcontent-ng-c1037862221="">Profit After Tax (PAT):</strong> Reported at Rs 610.23 million in Q1FY27, which represents a significant YoY jump of 150.73% from Rs 243.38 million in Q1FY26. On a QoQ basis, the PAT surged by 207.27% from Rs 198.60 million in Q4FY26. For FY26, the PAT was recorded at Rs 831.24 million.</li> <li _ngcontent-ng-c1037862221=""><strong _ngcontent-ng-c1037862221="">Total Comprehensive Income:</strong> Stood at Rs 611.73 million in Q1FY27, up by 150.34% YoY compared to Rs 244.36 million in Q1FY26, and showing a robust QoQ rise of 202.60% from Rs 202.16 million in Q4FY26. For the full year FY26, it was Rs 827.75 million.</li> </ul> <p _ngcontent-ng-c1037862221=""><strong _ngcontent-ng-c1037862221="">Business Highlights:</strong></p> <ul> <li _ngcontent-ng-c1037862221=""><strong _ngcontent-ng-c1037862221="">Segment Performance:</strong> The company operates under a single primary reportable segment, which is 'Speciality Chemicals'. Accordingly, no separate disclosures for segment information have been made.</li> <li _ngcontent-ng-c1037862221=""><strong _ngcontent-ng-c1037862221="">Initial Public Offering (IPO):</strong> Subsequent to Q1FY27, the company successfully completed its IPO of 7,396,437 equity shares (face value of Rs 2 each) at an issue price of Rs 676 per share, aggregating to Rs 5,000 million. The issue comprised an offer for sale of 6,213,006 equity shares aggregating to Rs 4,200 million and a fresh issue of 1,183,431 equity shares aggregating to Rs 800 million. The equity shares were listed on the NSE and BSE on September 16, 2026.</li> <li _ngcontent-ng-c1037862221=""><strong _ngcontent-ng-c1037862221="">IPO Expenditure:</strong> The company has incurred an expenditure of Rs 31.86 million (including Rs 2.64 million incurred during Q1FY27) in relation to the IPO. This amount is included under Other Current Assets and is proposed to be charged to the Securities Premium account once the IPO process is completed.</li> <li _ngcontent-ng-c1037862221=""><strong _ngcontent-ng-c1037862221="">Management Changes:</strong> The Board noted the retirement of Dr. Chitra Vaidya, Vice-President – R&D (Senior Management Personnel), effective from the close of business hours on September 30, 2026.</li> </ul> <p><a class="lb" href="/get-document/post/pdf/5869620/" target="_blank">Result PDF</a></p>

• Trendlyne
• 1 week 1 day ago